Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA ...

Basel, October 27, 2024 – Novartis today presented 12-month data from the Phase III APPEAR-C3G study at American Society of Nephrology (ASN) Kidney Week 2024 showing that patients with C3 ...

Novartis (NVS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Steve Scala from ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Physics-based US software specialist Schrödinger’s shares leapt nearly 14% to $22.25 on the back of news that it has entered ...

The previous update I wrote on Novartis was the Q2 earnings preview and I want to note that while my estimates on some of the key growth products were off, the general direction of my prediction ...

Operator Good morning and good afternoon, and welcome to the Novartis Q3 2024 results release conference call and live ...

DelveInsight’s Refractory Multiple Myeloma pipeline report depicts a robust space with 75+ active players working to develop ...

Narasimhan is confident that Novartis will achieve its goal of increasing sales by an average of 5% annually by 2028.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Novartis AG ( (NVS) ) has realeased its Q3 earnings. Here is a breakdown of the information Novartis AG presented to its investors. Novartis AG ...